It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate seen in healthy ...

Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company ...

Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have agreed to merge in an all-stock ...

Tis the season to resolve long-standing litigation in the U.S. | A week after Johnson & Johnson moved to resolve claims that ...

Gerresheimer, a Germany-based packaging company that specializes in drug delivery systems and glass and plastic packaging, ...

Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, ...

The three-year initiative is designed to generate 1.9 billion pound sterling ($2.5 billion) in annual cost savings by 2029, against 2.4 billion pound sterling in total one-time costs.  The cost ...

Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...

In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of ...

One panelist who voted ‘yes,’ Gabriel Alizaidy, M.D., of Maximus Health, argued that there was a “mismatch in real-world data ...

Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...